Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.
about
Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax.Rabies virus glycoprotein as a carrier for anthrax protective antigenAnthrax vaccination strategiesRabbit and nonhuman primate models of toxin-targeting human anthrax vaccinesAnthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challengeImmune correlates of protection against anthraxImmunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challengeImmunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxOral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Search for correlates of protective immunity conferred by anthrax vaccine.Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.Anthrax spores make an essential contribution to vaccine efficacyA recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challengeDirect inhibition of T-lymphocyte activation by anthrax toxins in vivo.The development of new vaccines against Bacillus anthracis.Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.Serological Correlate of Protection in Guinea Pigs for a Recombinant Protective Antigen Anthrax Vaccine Produced from Bacillus brevis.Immunoproteomically identified GBAA_0345, alkyl hydroperoxide reductase subunit C is a potential target for multivalent anthrax vaccine.Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge.Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.Bacillus anthracis, a story of nature subverted by man.A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaquesCombination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.Domain specificity of the human antibody response to Bacillus anthracis protective antigen.Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbedMolecular subtyping of Bacillus anthracis and the 2001 bioterrorism-associated anthrax outbreak, United States.Liposome-based cationic adjuvant formulations (CAF): past, present, and future.Anthrax lethal toxin and the induction of CD4 T cell immunity.Anthrax vaccines: present status and future prospects.Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis.Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus).Human immune responses to the UK human anthrax vaccine.
P2860
Q24795118-74769A84-C8E3-429A-AE7F-2DF7D171BBA1Q28391261-61FBB170-B280-4473-85FE-C504D7AB996FQ28392248-37FABE4D-BDBB-45D8-923B-DA60B068D4B7Q28398013-9827678E-BA70-4320-B089-A5B8716034EBQ30540217-28F976B3-1449-49D3-8ACA-B2E9AA1741B0Q30766920-8D30B4DF-05E0-45E3-BC58-A0AA9A97CCE2Q30859738-6FC3EAA2-9BF7-434D-80C9-D1CEEB267105Q32066443-58C9FA72-02D1-4B0C-B9B4-5D6C1BADB7F9Q33258307-860CACBA-CCB7-4740-BBBE-EDF30AB33E6DQ33284583-45EB0D1B-5B9D-4045-AEAF-FFE732EE12BBQ33334776-E7903A00-0D79-403B-BC7B-DA56668D73B7Q33396429-6927A823-8CA2-4D64-8BA7-D962DED619F3Q33883273-A5E7AA67-9F77-46BD-9025-2796829132F6Q34007168-68C0B02D-C940-4A56-A353-515DDB889AB1Q34034287-EC23811A-F41C-425C-B4FC-4EB92422843AQ34117857-08443568-55B5-4503-B6E6-9799A56853B4Q34119476-4DAFB625-F387-459A-A1B9-01281B5CB671Q34194628-5A7D1694-FB8A-4A94-A244-8E7C224C01C7Q34194649-B9B4B787-26F4-476E-821F-FA87CACE87C0Q34384018-74A9EDBA-D07E-4AFE-99F4-3360DA30A6BAQ34582387-8E0D455C-170B-42BA-81EB-C693F810BB20Q34700706-02B5AB27-B123-4337-85BF-C914601A38B1Q35026166-D59E9679-3167-4EC9-9C9B-5CBF19192F11Q35052264-0257345F-8E0F-407F-BF04-2FB8FC3DE492Q35106528-2E18D676-A564-478E-9842-78C8314C1FBAQ35783791-0EE4BE89-93E3-4A9D-894A-D790E8FB638FQ36030835-7FB8C013-E88B-4D28-BE09-C488853392B6Q36234189-55A82248-9753-4328-B12A-7F4C0AFF8D0DQ36378590-5659E874-A696-404E-A6E0-F824C51DBA68Q36576750-7C373341-9BEC-495D-9511-A7D715AE204CQ36876723-48957AA2-B1DC-4CD9-8DCA-901BCE01DFCCQ37191250-4022BB40-E48B-4165-87A4-A58B07E5D4B9Q37314121-75A61775-3BDD-49C5-82CF-86952030F37BQ37514354-8E98FCA3-7EAD-4F58-B1DB-56C55A8F800EQ38060730-C35B054B-A664-4B9C-87B7-61586C9B714DQ38132268-03968D1F-C2AF-4E6C-8306-F9886E96B587Q41755913-527AE5BE-EDAB-416F-84EF-AC16C98DB952Q44619427-0BA98D09-680F-44BE-B3FD-9255AE50755DQ44892507-636FB20D-8B16-4AFB-929E-6E161C4E62B6Q45162643-232DA9F5-BA35-4E06-8A07-9E73781F7832
P2860
Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Protective efficacy of a recom ...... ment of immunological markers.
@ast
Protective efficacy of a recom ...... ment of immunological markers.
@en
type
label
Protective efficacy of a recom ...... ment of immunological markers.
@ast
Protective efficacy of a recom ...... ment of immunological markers.
@en
prefLabel
Protective efficacy of a recom ...... ment of immunological markers.
@ast
Protective efficacy of a recom ...... ment of immunological markers.
@en
P2093
P1433
P1476
Protective efficacy of a recom ...... sment of immunological markers
@en
P2093
P304
P356
10.1016/S0264-410X(97)00268-5
P407
P50
P577
1998-05-01T00:00:00Z